PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder treatment from the region after an advisory panel reaffirmed a negative opinion of ...

Lumenis announced the launch of OptiLift, a dynamic muscle stimulation technology intended to improve lower eyelid laxity, ...

In an interview, Scholar Rock's chief medical officer talks about benefits seen in clinical trials of its muscle-targeted SMA ...

PTC Therapeutics said on Friday its inherited progressive muscle-wasting disorder drug will no longer be available for sale in the EU as the European Commission has decided not to renew its marketing ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Scholar Rock (SRRK) announced that the U.S. Food and Drug Administration FDA has accepted its Biologics License Application BLA for ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...